focus -WSS

focus

author：Wikipedia 2025-09-27 22:50:04 - browse：8333

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： CRISPR technology availability, affordability needs to be expanded

WSS

Readout LOUD podcast: Merger Mondays, Ozempic panic

Testing GLP

Better Therapeutics data on benefit with GLP

Biotech investment managers search for lucrative opportunities

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Chinese researcher claims birth of first gene

hotspot

focus

explore

Activists slam private health insurers over coverage restrictions

How clinical AI models' predictive power can degrade over time

Apple is now the first public company to be valued at $3 trillion

Surgeons perform first xenotransplant using CRISPR'd pig kidney

DIEP, the 'gold standard' of breast reconstruction, is under threat

Massive project maps cells in human brain in unprecedented detail

Alkermes shareholders re

Asbestos ban is immediate, but health effects will linger for decades

New air purifier tech could be key to improving indoor air quality

Life sciences deals on track to hit lowest point since 2017

hotspot

Peter Marks talks Operation Warp Speed for Rare Diseases

Female surgeons have lower rates of long

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Testing GLP

European regulators consider appeal over Amylyx ALS drug

Wellcome Trust names Røttingen as its new CEO

entertainment

explore

hotspot

focus